Loading

Medical Marijuana

  • by NORML January 11, 2018

    Oklahoma City: The National Organization for the Reform of Marijuana Laws (NORML) is proud to endorse Oklahoma’s State Question 788 — a statewide ballot measure that provides patients regulated access to medical cannabis. SQ 788 is a patient-centric plan that empowers physicians to use their discretion when determining their patient’s ideal health care plan.

    vote

    Oklahomans will go to vote on the measure on June 26.

    “We’re excited to offer NORML’s support to the Vote Yes On 788 campaign,” said NORML Outreach Director Kevin Mahmalji. “Together, we will build a broad-based coalition to ensure that lawmakers do not unduly interfere with the bonafide doctor-patient relationship, and that patients are no longer subject to arrest for accessing or growing this important medicine.”

    State Question 788 also establishes a licensed system of medical cannabis distribution.

    “State Question 788 was designed to make Oklahoma the most patient-oriented and business friendly state for the medical marijuana industry. SQ 788 will create jobs, sorely needed tax revenue, and possesse a number of patient protections that simply don’t exist in other states with similar laws,” said William Jones, campaign manager for the Vote Yes On 788 campaign.

    Under the plan, licensed medical marijuana patients may cultivate up to six mature plants, and may possess personal use quantities of marijuana flower, edibles, or infused concentrates. Statewide polling data finds that over 70 percent of residents endorse patients’ access to medical marijuana.

    “Recent nationwide polling shows 94 percent of US adults expressed their support for the legalization of medical marijuana, similarly the vast majority of Oklahomans are ready for a new direction. Regardless of the increasingly hostile from Attorney General Jeff Sessions, voters in Oklahoma and throughout the country will continue to support common sense marijuana law reforms over the failed policies of prohibition,” said NORML Outreach Director Kevin Mahmalji.

    Between now and June 26, representatives with the Vote Yes On 788 campaign will be traveling statewide and meeting face-to-face with voters. NORML will also be focusing its resources in the coming months to support these campaign efforts.

    ballot_box_leaf

    To follow the Yes on 788 campaign, click here. To donate to the campaign, click here.

    More details on SQ 788:

    Licenses would cost $100 and expire after two years. Those that are recipients of Medicaid, Medicare, or SoonerCare would pay $20 for a license. An individual 18 years or older who wants to obtain a medical marijuana license would need a board-certified physician’s signature and an individual under the age of 18 would need the signatures of two physicians and his or her parent or legal guardian. SQ 788 does not list specific qualifying conditions, thus giving more discretion to licensed physicians to determine wellness plans with their patients.

    3410000930_95fc2866fa_zUnder this initiative, employers, landlords, and schools are forbidden from penalizing persons for holding a medical marijuana license, unless failing to do so causes a loss of benefits under federal law or the license-holders possess or use marijuana while at work.

    Individuals possessing a medical marijuana license would be authorized to consume marijuana and possess up to three ounces, six mature and six seedling marijuana plants, up to one ounce of concentrated marijuana, up to 72 ounces of edible marijuana, and up to eight ounces of marijuana in their residences. However, possessing up to 1.5 ounces of marijuana without a license but with a medical condition would be deemed a misdemeanor.

    For additional information, contact NORML’s Outreach Director Kevin Mahmalji at: KevinM@norml.org.

  • by Paul Armentano, NORML Deputy Director January 5, 2018

    3410000930_95fc2866fa_zOklahoma voters will decide this June on State Question 788 — a statewide ballot measure legalizing the use, cultivation, and distribution of medical cannabis to qualified patients.

    Oklahomans will vote on the issue on June 26 during the primary election. Republican Mary Fallin set the date via an executive proclamation, issued yesterday.

    State Question 788 permits physicians to recommend cannabis therapy to patients at their discretion. Patients possessing a state-issued medical license are permitted to engage in cannabis possession or cultivation, or they purchase marijuana products from a licensed dispensary.

    Initiative proponents gathered sufficient signatures to place the issue before voters in 2016. However, the vote was postponed because of litigation over contested ballot title language. In a 7 to 1 ruling in April, justices rejected the state attorney general’s rewording of the initiative’s ballot title, which proponents had argued was purposely misleading, and ordered that the measure’s initial language be restored.

    Under Oklahoma law, the cultivation or distribution of cannabis is classified as a felony offense punishable by up to life in prison.

    Proponents of separate statewide medical cannabis initiatives are gathering signatures in Missouri and Utah. Proponents of a medical marijuana initiative in South Dakota have turned in their signatures and are awaiting a review by the Secretary of State’s office. In November, proponents of a voter initiative effort to legalize and regulate the personal use and retail sale of cannabis in Michigan turned in more than 360,000 signatures in an effort to qualify the measure for the November 2018 ballot.

  • by Justin Strekal, NORML Political Director November 29, 2017

    Congressman Dana Rohrabacher (R-CA) addresses NORML members in September, 2017

    Today, sixty-six members of Congress representing both Republicans and Democrats sent a letter to Speaker Ryan, Senate Majority Leader McConnell, Leader Pelosi, and Leader Schumer urging them to maintain the federal protections for the 46 states that have implemented some form of medical cannabis programs throughout the country.

    This comes on the same day the Attorney General Jeff Sessions held a press conference to discuss America’s opioid epidemic and made disparaging comments about marijuana.

    “We’re working on that very hard right now,” Sessions said on Wednesday. “We had meetings yesterday and talked about it at some length. It’s my view that the use of marijuana is detrimental and we should not give encouragement in any way to it. And it represents a federal violation which is in the law and is subject to being enforced, and our priorities will have to be focused on all the things and challenges that we face.”

    From Rep. Rohrabacher’s press release:

    Representatives Dana Rohrabacher (CA-48) and Earl Blumenauer (OR-03) spearheaded a letter, signed by 64 other members of the House of Representatives, urging House and Senate leadership to ensure the inclusion of medical marijuana protections in any appropriations bill that funds the government beyond December 8, 2017. The provision, previously known as “Rohrabacher-Farr,” and now “Rohrabacher-Blumenauer,” bars the Department of Justice from using appropriated funds to prosecute individuals who are acting in compliance with their state’s medical marijuana laws. The provision was first signed into law in December 2014 as part of a larger spending package, and has been in force ever since.

    Congressman Earl Blumenauer (D-OR) speaking a NORML Conference

    Reps Rohrabacher and Blumenauer are both co-chairs of the bipartisan Congressional Cannabis Caucus.

    In September, President Donald Trump reached an agreement with Congressional leadership to enact a three-month continuing resolution that maintains present federal spending levels and priorities through December 8, 2017, which included the amendment that was passed in the previous session of Congress.

    Congressional leadership must reauthorize this language as part of the forthcoming budget in order for the provisions to stay in effect. In July, Sen. Patrick Leahy (D-VT) offered identical language before the Senate Appropriations Committee, which approved it. However, House Rules Committee Chair Peter Sessions (R-TX) has refused to allow House members to vote on similar language. The provision will now be considered by House and Senate leadership when the two chambers’ appropriations bills are reconciled.

    It is imperative that the Rohrabacher-Blumenauer amendment remain the law of the land and AG Sessions not be given the green-light to enact a crackdown. Click here to send a message to your federal lawmakers and urge them to speak out about the need to protect the 2 million registered medical marijuana patients throughout the country.

  • by Justin Strekal, NORML Political Director November 2, 2017

    IMG_2898 copyIn a new poll of US service veterans conducted by The American Legion and presented today on Capitol Hill, one in five veterans self-reported using marijuana to alleviate a medical or physical condition.

    Flanked by lawmakers including Reps Tim Walz, Mark Takano, Julia Brownley, and Matt Gaetz, veterans presented their own personal stories of the efficacy of marijuana as a therapeutic treatment for a litany of conditions.

    Other notable data points revealed by the survey:

    •  81% of veterans support federally-legal treatment
    • 60% of respondents do not live in states where medical cannabis is legal
    • 40% of respondents live in states where medical cannabis is legal
    • And the partisan divide is nearly non-existent:
      • 88% of self-identified conservative respondents support federally legalized medical
        cannabis
      • 90% of self-identified liberal respondents support federally legalized medical
        cannabis
      • 70% of self-identified non-partisan respondents support federally legalized medical
        cannabis

    My favorite data point from their poll: 100% of respondents aged 18-30 support federally legalized medical cannabis.

    You can support the same legislation that the American Legion supports, the Veterans Equal Access Act, which would allow those who have served our country to discuss and be recommended medical marijuana in the states that have implemented programs by CLICKING HERE. 

  • by Paul Armentano, NORML Deputy Director November 1, 2017

    GovChristieDespite the growing body of scientific evidence showing that cannabis access is associated with reductions in opioid use and mortality, the Chairman of the White House’s Commission on Combating Drug Addiction and the Opioid Crisis today called upon the President to reject any efforts to acknowledge marijuana’s promising role in mitigating opioid abuse and dependency.

    In a letter sent today to President Donald Trump by New Jersey Gov. Chris Christie, Chairman of the Committee, he writes:

    “The Commission acknowledges that there is an active movement to promote the use of
    marijuana as an alternative medication for chronic pain and as a treatment for opioid addiction. … There is a lack of sophisticated outcome data on dose, potency, and abuse potential for marijuana. This mirrors the lack of data in the 1990’s and early 2000’s when opioid prescribing multiplied across health care settings and led to the current
    epidemic of abuse, misuse and addiction. The Commission urges that the same mistake is not made with the uninformed rush to put another drug legally on the market in the midst of an overdose epidemic.”

    President Trump established the Commission in May via an executive order. Members of the Commission issued their policy recommendations today.

    In recent months, dozens of peer-reviewed studies have concluded that legal cannabis access is associated with reduced rates of opioid use, spending, abuse, hospitalization, and mortality. Summaries and links to these studies are available here.

    Despite over 10,000 advocates communicating this information to the Commission, members of the committee have chosen to disregard it. Moreover, Gov. Christie opines in today’s letter that cannabis exposure increases the likelihood that one will become opioid dependent — an allegation that was recently rejected by the National Academy of Sciences, which, in a January 2017 review of some 10,000 peer-reviewed studies, failed to identify even one “good or fair-quality systematic review that reported on the association between cannabis use and the initiation of use of opioids.”

    NORML thanks the thousands of you who took the time to try to inform and educate this Commission and regrets that its members continue to place political ideology above the health and safety of American lives.

Page 4 of 512345